Acumapimod

An inhibitor of p38α MAPK

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥912.00

730.00

- +
10mg

￥1400.00

1120.00

- +
25mg

￥2812.00

2250.00

- +
50mg

￥4412.00

3530.00

- +
100mg

￥7125.00

5700.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 uM for p38α.

Acumapimod is an inhibitor of p38α with an IC50 value of less than 1 uM.

BCT197 is an oral low-molecular-weight p38 inhibitor currently in development for the treatment of several inflammatory conditions, including chronic obstructive pulmonary disease (COPD). Intermittent short-term dosing of BCT197 (75 mg on days 1 and 6) shows a marked improvement in lung function in COPD patients[2].

参考文献:
[1]. Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92.
[2]. De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700.